BrightGene not to redeem "Borui convertible bonds" despite conditions met

BrightGene Bio-Medical Technology announced its decision not to prematurely redeem its "Borui Convertible Bonds" after triggering the conditional redemption clause. From August 22 to September 11, 2025, the company's stock price met the condition of closing at or above 130% of the current conversion price (RMB 45.16/share) for at least 15 trading days within a 30-trading day period. This decision, approved by the board of directors on September 11, 2025, considers the company's operational status, stock performance, market conditions, and its commitment to long-term development.

The company further stated that should the "Borui Convertible Bonds" again trigger the conditional redemption clause within the next three months (September 12, 2025, to December 11, 2025), it will still not exercise its early redemption right. The initial conversion price of RMB 35.68/share, established on July 11, 2022, has undergone several adjustments due to equity distributions, most recently changing to RMB 34.74/share on June 23, 2025.

Minsheng Securities, as the sponsor institution, confirmed that BrightGene's decision aligns with relevant regulations and the prospectus for the convertible bonds, having undergone the necessary decision-making procedures. No related parties, including the actual controller, controlling shareholders, or senior management, traded "Borui Convertible Bonds" in the six months prior to the redemption condition being met.